Leonabio Inc (LONA)

May 05, 2026

MSN Money - MSN

May 05, 2026

Apr 27, 2026

LONA Earnings History & Surprises | EPS & Revenue Results | LEONABIO INC (NASDAQ:LONA) - ChartMill

Apr 27, 2026

Apr 24, 2026

LONA LeonaBio reports sharply worse than expected Q4 2025 EPS, shares drop 3.36% on investor disappointment.Sector Underperform - Newser

Apr 24, 2026

Apr 23, 2026

Athira Pharma (LONA) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $LONA - MarketBeat

Apr 23, 2026

Apr 23, 2026

LeonaBio to Host Virtual Key Opinion Leader Event Highlighting Potential of Lasofoxifene in Treatment-Resistant ER+/HER2-, ESR1-Mutated Metastatic Breast Cancer - Yahoo Finance

Apr 23, 2026

Apr 21, 2026

LeonaBio (LONA) Showcases Lasofoxifene Research at AACR26 - GuruFocus

Apr 21, 2026

Apr 21, 2026

Independent Nonclinical Research on Lasofoxifene Presented at American Association for Cancer Research Annual Meeting 2026 Consistent with LeonaBio’s Data - The Manila Times

Apr 21, 2026

Apr 21, 2026

Independent Nonclinical Research on Lasofoxifene Presented - GlobeNewswire

Apr 21, 2026

Apr 20, 2026

LeonaBio (LONA) Stock: Is It Testing Levels (Overhead Buying) 2026-04-20Earnings Miss Stocks - Xã Thanh Hà

Apr 20, 2026

Apr 13, 2026

28,000-share stock option grant to LeonaBio (LONA) director - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) awards 300,000 stock options to chief scientific officer - Stock Titan

Apr 13, 2026

Apr 13, 2026

28,000 stock options granted to LeonaBio (LONA) director Kosacz - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) director Grant Pickering receives 28,000 stock options - Stock Titan

Apr 13, 2026

Apr 13, 2026

Director Romano Kelly receives 28,000 LeonaBio (LONA) stock options at $9.54 - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) director receives options to buy 28,000 shares at $9.54 - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) director awarded options on 28,000 shares at $9.54 - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) grants CMO 350,000 options at $9.54 - Stock Titan

Apr 13, 2026

Apr 13, 2026

Director John M. Fluke Jr. receives 28,000-share option grant at LeonaBio (LONA) - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) awards 300,000 stock options to general counsel - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) CFO awarded 300,000 stock options at $9.54 - Stock Titan

Apr 13, 2026

Apr 13, 2026

LeonaBio (LONA) CEO awarded 750,000 stock options at $9.54 strike - Stock Titan

Apr 13, 2026

Apr 12, 2026

LONA: LeonaBio, Inc.Comparison to Industry - Zacks Investment Research

Apr 12, 2026

Apr 09, 2026

Leonabio discovers new pannexin-1 inhibitors - BioWorld News

Apr 09, 2026

Apr 08, 2026

What is driving long-term growth of LeonaBio (LONA) Stock | Price at $11.68, Up 6.28%Fast Rising Picks - Newser

Apr 08, 2026

Apr 08, 2026

LONA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI

Apr 08, 2026

Apr 07, 2026

Cantor Fitzgerald reiterates Overweight on LeonaBio stock By Investing.com - Investing.com Canada

Apr 07, 2026

Apr 07, 2026

Cantor Fitzgerald reiterates Overweight on LeonaBio stock - Investing.com

Apr 07, 2026

Apr 06, 2026

Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook By Investing.com - Investing.com South Africa

Apr 06, 2026

Apr 06, 2026

Mizuho raises LeonaBio stock price target to $16 on breast cancer drug outlook - Investing.com India

Apr 06, 2026

Apr 06, 2026

Mizuho Raises Price Target on LeonaBio to $16 From $10, Keeps Outperform Rating - marketscreener.com

Apr 06, 2026

Apr 02, 2026

[EFFECT] LeonaBio, Inc. SEC Filing - Stock Titan

Apr 02, 2026

Apr 02, 2026

Leonabio Warns of Major Financial and Operational Risks in Lasofoxifene Program Integration - TipRanks

Apr 02, 2026

Mar 31, 2026

LeonaBio (ATHA) clears resale of 5.5M warrant shares for Sermonix - Stock Titan

Mar 31, 2026

Mar 31, 2026

LeonaBio (NASDAQ: LONA) files resale registration for PIPE warrant holders - Stock Titan

Mar 31, 2026

Mar 31, 2026

LeonaBio (NASDAQ: ATHA) leans on breast cancer and ALS drugs - Stock Titan

Mar 31, 2026

Mar 31, 2026

LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - Stock Titan

Mar 31, 2026

Mar 27, 2026

LeonaBio Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 27, 2026

Mar 27, 2026

LeonaBio Reports 2025 Financial Results, Acquires Lasofoxifene License, and Advances Clinical Pipeline for Metastatic Breast Cancer and ALS 123 - Minichart

Mar 27, 2026

Mar 26, 2026

LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks

Mar 26, 2026

Mar 26, 2026

LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan

Mar 26, 2026

Mar 26, 2026

LeonaBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com

Mar 26, 2026

Mar 26, 2026

LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update - Bitget

Mar 26, 2026

Mar 25, 2026

LeonaBio, Inc. announced that it has received $89.724073 million in funding - MarketScreener

Mar 25, 2026

Mar 25, 2026

LeonaBio (LONA) Stock Analysis Report | Financials & Insights - Benzinga Japan

Mar 25, 2026

Mar 20, 2026

LeonaBio, Inc. Adopts 2026 Equity Incentive Plan and Amends Certificate of Incorporation – SEC 8-K Filing March 2026 - Minichart

Mar 20, 2026

Mar 19, 2026

LeonaBio shareholders approve equity plan and increase in authorized shares - Investing.com India

Mar 19, 2026

Mar 19, 2026

Form 8K LeonaBio Inc For: 19 March - Investing.com

Mar 19, 2026